Fecal Immunochemical Test Effective for Annual Colon Cancer Screening
By LabMedica International staff writers Posted on 10 Feb 2016 |
Image: The fecal immunochemical test (FIT) kit used in screening for colorectal cancer (Photo courtesy of Kaiser Permanente).
The fecal immunochemical test (FIT) is highly sensitive for detecting colorectal cancer, and adherence to annual follow-up screening among initial participants is high, making the noninvasive test feasible and effective for annual colorectal cancer screening programs.
Colorectal cancer (CRC) is the second leading cause of cancer death in the USA. Evidence shows that highly sensitive guaiac-based fecal occult blood tests (FOBT), which are recommended for annual screening of average risk patients between the ages of 50 and 75, can reduce morbidity and mortality from colorectal cancer. FIT has higher detection rates for CRC and advanced adenomas than FOBT, but little is known about how well FIT works over several rounds of annual screening.
Scientists working for Kaiser Permanente (Oakland, CA, USA) and their colleagues carried out a retrospective cohort study and collected data on 323,349 health plan members aged 50 to 70 years. The members were on their FIT mailing date in 2007 or 2008 and had completed the first round of FIT and were followed for up to four screening rounds. Screening participation included an FIT positivity, equal to or greater than 20 µg of hemoglobin/g, which has positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.
Of the patients invited for screening, 48.2% participated in round one. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of first round participants crossed over to endoscopy over four screening rounds and 7.0% were due to a positive FIT result. The FIT positivity rate of 5.0% and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in the first round.
Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within one year of testing, including 84.5% in round one and 73.4% to 78.0% in subsequent rounds. The authors concluded that annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening. The study was published on January 26, 2016, in the journal Annals of Internal Medicine.
Related Links:
Kaiser Permanente
Colorectal cancer (CRC) is the second leading cause of cancer death in the USA. Evidence shows that highly sensitive guaiac-based fecal occult blood tests (FOBT), which are recommended for annual screening of average risk patients between the ages of 50 and 75, can reduce morbidity and mortality from colorectal cancer. FIT has higher detection rates for CRC and advanced adenomas than FOBT, but little is known about how well FIT works over several rounds of annual screening.
Scientists working for Kaiser Permanente (Oakland, CA, USA) and their colleagues carried out a retrospective cohort study and collected data on 323,349 health plan members aged 50 to 70 years. The members were on their FIT mailing date in 2007 or 2008 and had completed the first round of FIT and were followed for up to four screening rounds. Screening participation included an FIT positivity, equal to or greater than 20 µg of hemoglobin/g, which has positive predictive values for adenoma and CRC, and FIT sensitivity for detecting CRC obtained from Kaiser Permanente electronic databases and cancer registries.
Of the patients invited for screening, 48.2% participated in round one. Of those who remained eligible, 75.3% to 86.1% participated in subsequent rounds. Median follow-up was 4.0 years, and 32% of first round participants crossed over to endoscopy over four screening rounds and 7.0% were due to a positive FIT result. The FIT positivity rate of 5.0% and positive predictive values (adenoma, 51.5%; CRC, 3.4%) were highest in the first round.
Overall, programmatic FIT screening detected 80.4% of patients with CRC diagnosed within one year of testing, including 84.5% in round one and 73.4% to 78.0% in subsequent rounds. The authors concluded that annual FIT screening was associated with high sensitivity for CRC, with high adherence to annual follow-up screening among initial participants. The findings indicate that annual programmatic FIT screening is feasible and effective for population-level CRC screening. The study was published on January 26, 2016, in the journal Annals of Internal Medicine.
Related Links:
Kaiser Permanente
Latest Pathology News
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy